Osimertinib Plus Savolitinib Shows Activity in EGFR-Mutant, MET-Amplified NSCLC

The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

HR001 was found to have an efficacious response for patients with relapsed/refractory non-Hodgkin lymphoma.

ONCOLOGY spoke with Eric Ko, MD, PhD, who recently published a review article with his colleagues on strategies for combining radiation therapy with immunotherapy for the treatment of non–small-cell lung cancer.

Investigators also look to assess linvoseltamab in relapsed/refractory multiple myeloma as part of the phase 3 LINKER-MM3 trial.

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.